Polaryx Therapeutics, Inc.

What they do

Polaryx develops disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its pipeline includes PLX-200, an oral reformulated gemfibrozil in a Phase 2 proof-of-concept basket trial called SOTERIA, as well as earlier-stage candidates PLX-300, PLX-100, and PLX-400. The company has no approved products and generates no product revenue; it is advancing clinical development.

Revenue drivers

• PLX-200 (SOTERIA Phase 2 trial) — Most advanced candidate, an oral small molecule pursued through a 505(b)(2) pathway for CLN2, CLN3, Krabbe disease, and Sandhoff disease; no revenue yet.
• PLX-300 — Novel oral small molecule in IND-enabling studies for LSDs; no revenue.
• PLX-100 — Preclinical oral combination therapy (PLX-200 plus vitamin A) for LSDs; no revenue.
• PLX-400 — Preclinical gene therapy for LSDs; no revenue.

Recent performance

Polaryx reported a net loss of $9.0 million for 2025, compared with a net loss of $30.4 million for 2024. Diluted EPS was $(0.20) for 2025 versus $(0.89) for 2024. Operating cash flow was negative $3.9 million for 2025 and negative $2.6 million for 2024. As of June 30, 2026, the company reported total assets of $11.8 million, total liabilities of $0.873 million, shareholder equity of $10.9 million, and cash and equivalents of $11.5 million.

Strategy

Polaryx is focused on advancing PLX-200 through the Phase 2 SOTERIA basket trial, which it expects to initiate in the second half of 2026. In July 2026, it amended the trial design, expanding the Sandhoff and Krabbe cohorts from three to six participants each, raising total enrollment from 18 to 24. The company believes data readouts could support potentially registrable trials for each of the four indications and may support seeking expedited approval for CLN2 and CLN3. It also maintains earlier-stage programs PLX-300, PLX-100, and PLX-400.

Risks

• No approved products or revenue — The company has no products approved for commercial sale and a limited operating history, and its results may vary from quarter to quarter.
• Clinical trial timing and execution — SOTERIA initiation is expected in the second half of 2026, and prior PLX-200 trials in CLN2 and CLN3 were delayed by COVID-19 and a strategy shift.
• Regulatory approval uncertainty — The company's strategy relies on the 505(b)(2) pathway and potential accelerated approval, and receipt of designations such as orphan drug or Fast Track does not guarantee faster development or approval.
• Cash needs and equity dilution — With $11.5 million in cash and equivalents as of June 30, 2026, and negative operating cash flow, the company may need additional capital, which could dilute shareholders.

Outlook

Management expects to initiate the Phase 2 SOTERIA trial in the second half of 2026, following a July 2026 amendment that increased enrollment to 24 participants. Data readouts are expected to provide guidance for potentially registrable trials in CLN2, CLN3, Krabbe disease, and Sandhoff disease. The company also believes there may be an opportunity to seek expedited approval for PLX-200 in CLN2 and CLN3 based on precedent approval of a third-party drug with a similar trial design.